VNDA

Business Context and Reporting Period

Company: Vanda Pharmaceuticals Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006
Business Overview: Vanda is a clinical-stage biopharmaceutical company focused on central nervous system disorders. It holds exclusive worldwide commercial rights to three product candidates: Iloperidone (schizophrenia/bipolar disorder), VEC-162 (sleep/mood disorders), and VSF-173 (excessive sleepiness). The company has no approved products and generates no product revenue.

Key Financial Metrics (Year Ended Dec 31, 2006)

Note: The company had no long-term debt as of December 31, 2006, having settled its equipment credit facility in September 2006.

Material Changes vs. Prior Period

• Operating Loss Expansion: Net loss increased by approximately 166% to $63.5 million, driven primarily by a 208% increase in R&D expenses ($35.2 million increase) due to the execution of Phase III trials for Iloperidone and VEC-162.
• Public Offerings: The company consummated an Initial Public Offering (IPO) in April 2006, raising net proceeds of approximately $53.3 million. A follow-on offering in January 2007 raised an additional $110.9 million (subsequent to the reporting period).
• Stock-Based Compensation: Total stock-based compensation expense was $6.1 million in 2006, compared to $5.1 million in 2005, following the adoption of SFAS 123(R).
• Cash Flow: Net cash used in operating activities increased to $51.6 million in 2006 from $17.7 million in 2005. Net cash provided by financing activities was $53.3 million, primarily from the IPO.

Guidance, Outlook, and Risks

Management Outlook

• Iloperidone: Positive Phase III results announced in December 2006. Management expects to file a New Drug Application (NDA) with the FDA by the end of 2007.
• VEC-162: Positive Phase III results for transient insomnia announced in November 2006. Additional Phase III trials for chronic sleep disorders are expected to begin in the second half of 2007.
• VSF-173: Phase II trial for excessive sleepiness expected to begin in mid-2007.
• Liquidity: Management believes existing cash, including proceeds from the January 2007 follow-on offering, will fund operations through early 2008. Additional capital will be required thereafter.

Key Risks and Contingencies

• Regulatory Approval: No products are approved. Success depends on FDA approval of NDAs, which is not guaranteed.
• Capital Requirements: The company has a history of losses and expects to incur substantial losses for the foreseeable future. Failure to secure additional funding could force delays or termination of development programs.
• Intellectual Property: Rights to all three product candidates are licensed from third parties (Novartis and Bristol-Myers Squibb). Rights may terminate if milestones are not met or if the company fails to maintain financial conditions.
• Market Acceptance: Even if approved, products must compete with established therapies and gain acceptance from physicians and payors.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $110.9 million follow-on proceeds (Jan 2007) combined with year-end 2006 cash to fund the planned NDA filing and commercial launch preparations through 2008.
• License Agreements: Review the specific milestone payment obligations and termination clauses in the Novartis (Iloperidone, VSF-173) and BMS (VEC-162) agreements.
• Clinical Trial Data: Confirm the statistical significance and safety profile details of the Phase III trials for Iloperidone and VEC-162 as presented in the filing.
• Patent Expirations: Note the patent expiration dates (Iloperidone: 2011 US; VEC-162: 2017 US; VSF-173: 2014 US) and the reliance on Hatch-Waxman extensions for exclusivity.
• Stock Dilution: Assess the impact of the 1.7 million outstanding options and the potential for future equity raises on shareholder value.